The enrollment completion is operationally positive, but the data delay to Q1 2027 removes a near-term catalyst and introduces uncertainty about the dataset's strength. Watch for any interim biomarker or safety updates before Q1 2027, and for initiation of the FSHD Phase 2 trial in Q4 2026 as a secondary catalyst.
Price Chart
Executive Summary
Satellos Bioscience completed enrollment for BASECAMP, its Phase 2 trial of forazapadin in Duchenne muscular dystrophy, exceeding the target in under nine months. The company delayed topline data release to Q1 2027 to compile a more complete dataset, which pushes back a key catalyst but signals confidence in the data's quality.
Key Facts
- BASECAMP Phase 2 trial enrollment completed, exceeding target in <9 months across 18 global sites
- Topline clinical data now expected in Q1 2027 (previously planned earlier)
- Trial randomized 1:1:1 to forazapadin 60 mg, 120 mg, or placebo in ambulatory boys 7–10 years old
- Primary endpoints: safety, tolerability, muscle force by dynamometry; secondary endpoints assess muscle quality, function, regeneration
- Phase 2 FSHD study expected to begin Q4 2026
Financial Impact
No financial figures disclosed; clinical-stage company with no approved products or revenue
Risk Factors
- Data delay may disappoint investors expecting earlier readout
- Phase 2 results could fail to meet primary or secondary endpoints
- Company is pre-revenue and will require future financing to fund operations and trials
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3371742 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers